mtm laboratories Announces the European Launch of CINtec(R) PLUS - Gilde Healthcare

mtm laboratories Announces the European Launch of CINtec(R) PLUS

8 maart 2010

Powerful new biomarker combination for cervical cancer screening 

mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.*

CINtec® PLUS combines the p16 biomarker, widely validated for diagnostic purposes, with the proliferation marker Ki-67. By combining these two markers in a single diagnostic test, CINtec® PLUS provides both high sensitivity and high specificity for detecting high-grade cervical disease. The performance of this test for highly accurate detection of pre-cancerous cervical lesions has been demonstrated in three clinical trials conducted in over 30,000 women across Europe. In these studies, CINtec® PLUS was demonstrated to have significant clinical utility across a wide range of applications in cervical cancer screening and management.

“The combination of both high sensitivity and specificity in a single test is what sets CINtec® PLUS apart from currently available diagnostic tests”

said Robert Silverman, CEO of mtm laboratories,

“What this means for patients and clinicians is that early stage disease can be identified accurately in time for effective medical intervention. In comparison to the currently available technologies, CINtec® PLUS will minimize over or under diagnosis.”

CINtec® PLUS is the newest in a line of diagnostic and screening tests using the p16 biomarker that have been developed by mtm laboratories. CINtec® Histology and CINtec® Cytology are already marketed in Europe and were launched in 2007.
 
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com

Gilde Healthcare company Big Health receives US FDA Clearance for DaylightRx

First FDA cleared non-drug treatment for generalized anxiety disorder. Clearance is the second FDA-clearance for Big Health. Big Health, a leading developer of digital mental health treatments, has been granted clearance by the U.S. Food...
5 september 2024

Gilde Healthcare company Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline Appointment follows achievement of three key milestones for Amphista...
3 september 2024

Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations

Gilde Healthcare, the transatlantic specialist investment firm, is pleased to announce the addition of Jan Willem Bakker to its team as Partner & Head of Investor Relations. Jan Willem will focus on Gilde Healthcare’s investor...
2 september 2024